Emergence and Transmission of Drug-/Multidrug-resistant Mycobacterium leprae in a Former Leprosy Colony in the Brazilian Amazon.
M. leprae
leprosy
multidrug resistance
primary resistance
transmission
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 05 2020
06 05 2020
Historique:
received:
02
04
2019
accepted:
28
06
2019
pubmed:
2
7
2019
medline:
7
1
2021
entrez:
2
7
2019
Statut:
ppublish
Résumé
Leprosy has been treated with multidrug therapy, which has been distributed for free across the globe and regarded as highly efficient. However, the impossibility of growing Mycobacterium leprae in axenic media has historically impaired assessments of M. leprae resistance, a parameter only recently detectable through molecular methods. A systematic, population-based search for M. leprae resistance in suspected leprosy relapse cases and contacts was performed in Prata Village, an isolated, hyperendemic, former leprosy colony located in the Brazilian Amazon. Results led to an extended active search involving the entire Prata population. Confirmed leprosy cases were investigated for bacterial resistance using a combination of in vivo testing and direct sequencing of resistance genes folP1, rpoB, and gyrA. A molecular epidemiology analysis was performed using data from 17 variable number tandem repeats (VNTR). Mycobacterium leprae was obtained from biopsies of 37 leprosy cases (18 relapses and 19 new cases): 16 (43.24%) displayed drug-resistance variants. Multidrug resistance to rifampicin and dapsone was observed in 8 relapses and 4 new cases. Single resistance to rifampicin was detected in 1 new case. Resistance to dapsone was present in 2 relapses and 1 new case. Combined molecular resistance and VNTR data revealed evidence of intra-familial primary transmission of resistant M. leprae. A comprehensive, population-based systematic approach to investigate M. leprae resistance in a unique population revealed an alarming scenario of the emergence and transmission of resistant strains. These findings may be used for the development of new strategies for surveillance of drug resistance in other populations.
Sections du résumé
BACKGROUND
Leprosy has been treated with multidrug therapy, which has been distributed for free across the globe and regarded as highly efficient. However, the impossibility of growing Mycobacterium leprae in axenic media has historically impaired assessments of M. leprae resistance, a parameter only recently detectable through molecular methods.
METHODS
A systematic, population-based search for M. leprae resistance in suspected leprosy relapse cases and contacts was performed in Prata Village, an isolated, hyperendemic, former leprosy colony located in the Brazilian Amazon. Results led to an extended active search involving the entire Prata population. Confirmed leprosy cases were investigated for bacterial resistance using a combination of in vivo testing and direct sequencing of resistance genes folP1, rpoB, and gyrA. A molecular epidemiology analysis was performed using data from 17 variable number tandem repeats (VNTR).
RESULTS
Mycobacterium leprae was obtained from biopsies of 37 leprosy cases (18 relapses and 19 new cases): 16 (43.24%) displayed drug-resistance variants. Multidrug resistance to rifampicin and dapsone was observed in 8 relapses and 4 new cases. Single resistance to rifampicin was detected in 1 new case. Resistance to dapsone was present in 2 relapses and 1 new case. Combined molecular resistance and VNTR data revealed evidence of intra-familial primary transmission of resistant M. leprae.
CONCLUSIONS
A comprehensive, population-based systematic approach to investigate M. leprae resistance in a unique population revealed an alarming scenario of the emergence and transmission of resistant strains. These findings may be used for the development of new strategies for surveillance of drug resistance in other populations.
Identifiants
pubmed: 31260522
pii: 5526733
doi: 10.1093/cid/ciz570
pmc: PMC7201420
doi:
Substances chimiques
Leprostatic Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2054-2061Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Jpn J Infect Dis. 2010 Jan;63(1):1-7
pubmed: 20093754
Clin Microbiol Infect. 2018 Dec;24(12):1305-1310
pubmed: 29496597
Lancet. 1976 Dec 11;2(7998):1304-5
pubmed: 63780
Lancet Infect Dis. 2018 Feb;18(2):135-137
pubmed: 29412953
Lepr Rev. 2012 Sep;83(3):269-81
pubmed: 23356028
Nat Commun. 2018 Jan 24;9(1):352
pubmed: 29367657
Clin Microbiol Infect. 2014 Oct;20(10):O619-22
pubmed: 24612452
Lancet Infect Dis. 2017 Sep;17(9):e293-e297
pubmed: 28693853
J Clin Microbiol. 2014 Dec;52(12):4359-60
pubmed: 25274993
Lepr Rev. 1996 Dec;67(4):280-6
pubmed: 9033198
J Clin Microbiol. 2012 Jun;50(6):1912-7
pubmed: 22495562
Science. 2016 Nov 11;354(6313):744-747
pubmed: 27846605
J Antimicrob Chemother. 2017 Oct 1;72(10):2943-2944
pubmed: 29091204
J Glob Antimicrob Resist. 2018 Mar;12:214-219
pubmed: 29097343
PLoS Negl Trop Dis. 2017 Dec 15;11(12):e0006117
pubmed: 29244821
World Health Organ Tech Rep Ser. 1982;675:1-33
pubmed: 6806990
Lancet. 1964 Sep 26;2(7361):673-4
pubmed: 14188912
Lancet. 1997 Jan 11;349(9045):103-4
pubmed: 8996430
Lepr Rev. 1977 Jun;48(2):129-32
pubmed: 330999
Front Microbiol. 2018 Dec 13;9:3072
pubmed: 30619157
J Infect Dis. 2010 May 15;201(10):1598-605
pubmed: 20388034
Clin Infect Dis. 2016 Dec 1;63(11):1482-1484
pubmed: 27558568
J Exp Med. 1960 Sep 1;112(3):445-54
pubmed: 19867175
PLoS Negl Trop Dis. 2016 Oct 5;10(10):e0005041
pubmed: 27706165